ReviewCancers2020
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Predictors and Risk Assessment Models for Venous Thromboembolism in Patients Diagnosed with Lymphoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Cerebral Venous Sinus Thrombosis Revealing ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Inherited Thrombophilia and Concomitant Infection: Case Report and Narrative Review.Life (Basel, Switzerland) · 2026Article
- Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Article
- Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025Review
- Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: a retrospective cohort of 790 patients.BMC cancer · 2025Article
- Predictors of Complications in Patients Undergoing Port Catheter Application: A Comparative Study.Asian Pacific journal of cancer prevention : APJCP · 2025Observational
- Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study.HemaSphere · 2025Article
- Extracellular Vesicles Profile and Risk of Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma.International journal of molecular sciences · 2025Article
- Venous thromboembolic risk in hematological hospitalized patients: a retrospective study.Annals of hematology · 2025Observational
- Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk.International journal of molecular sciences · 2025Article
- Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non-Hodgkin Lymphoma Patients.Cancer medicine · 2024Article
- Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience.Annals of hematology · 2024Article
- Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis.The oncologist · 2024Article
- Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey.Diagnostics (Basel, Switzerland) · 2024Article
- The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma.Journal of clinical medicine · 2024Article
- Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels.Blood advances · 2023Article
- Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience.Cancers · 2022Article
- Central venous catheter-associated complications in pediatric patients diagnosed with Hodgkin lymphoma: implications for catheter choice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism (VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the literature of the last 20 years for reports identifying these risk factors in cohorts consisting exclusively of lymphoma patients. We selected 25 publications. The most frequent studies were analyses of retrospective single-center cohorts. We also included two reports of pooled analyses of clinical trials, two meta-analyses, two analyses of patient registries, and three analyses of population-based databases. The VTE risk is the highest upfront during the first two months after lymphoma diagnosis and decreases over time. This upfront risk may be related to tumor burden and the start of chemotherapy as contributing factors. Factors consistently reported as VTE risk factors are aggressive histology, a performance status ECOG ≥ 2 leading to increased immobility, more extensive disease, and localization to particular sites, such as central nervous system (CNS) and mediastinal mass. Association between laboratory values that are part of risk assessment models in solid tumors and VTE risk in lymphomas are very inconsistent. Recently, VTE risk scores for lymphoma were developed that need further validation, before they can be used for risk stratification and primary prophylaxis. Knowledge of VTE risk factors in lymphomas may help in the evaluation of the individual risk-benefit ratio of prophylaxis and help to design prospective studies on primary prophylaxis in lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.